Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Assets (2017 - 2025)

Inmune Bio (INMB) has disclosed Assets for 9 consecutive years, with $32.4 million as the latest value for Q4 2025.

  • Quarterly Assets fell 18.23% to $32.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $32.4 million through Dec 2025, down 18.23% year-over-year, with the annual reading at $32.4 million for FY2025, 18.23% down from the prior year.
  • Assets hit $32.4 million in Q4 2025 for Inmune Bio, down from $33.4 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $107.7 million in Q3 2021 to a low of $32.4 million in Q4 2025.
  • Historically, Assets has averaged $63.9 million across 5 years, with a median of $61.7 million in 2021.
  • Biggest five-year swings in Assets: skyrocketed 178.21% in 2021 and later tumbled 36.8% in 2025.
  • Year by year, Assets stood at $99.9 million in 2021, then fell by 18.16% to $81.8 million in 2022, then tumbled by 30.31% to $57.0 million in 2023, then plummeted by 30.59% to $39.6 million in 2024, then decreased by 18.23% to $32.4 million in 2025.
  • Business Quant data shows Assets for INMB at $32.4 million in Q4 2025, $33.4 million in Q3 2025, and $37.7 million in Q2 2025.